News & media

CAMBRIDGE, Mass., September 11, 2018 — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced a research collaboration with Fondazione Telethon, founder of the Telethon Institute of Genetics and Medicine (TIGEM), to develop new therapies for lysosomal storage disorders and more common disorders such as neurodegeneration. TIGEM, an international research […]

CAMBRIDGE, Mass., Dec. 6, 2018 – Casma Therapeutics, Inc. today announced an exclusive and nonexclusive license to technology developed at The University of Texas Southwestern Medical Center that will advance the company’s drive to harness the natural cellular processes of autophagy to design powerful new medicines for a broad range of diseases.The license includes commercial rights to a […]

CAMBRIDGE, Mass. – Dec. 12, 2018 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of two senior executives who will help lead Casma through its next phase of growth. Caren Block, Casma’s new vice president of people & culture, has extensive experience in […]

CAMBRIDGE, Mass. – March 26, 2019 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointments of Sascha Martens, Ph.D., and Pietro De Camilli, M.D., as the first members of Casma’s scientific advisory board. Martens, an expert in autophagy research, is currently professor and head […]

CAMBRIDGE, Mass. – April 12, 2019 – Casma Therapeutics, a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that the company has been named a winner of the Best Places to Work award sponsored by the Boston Business Journal. The Boston Business Journal’s Best Places to Work awards are designed to honor […]

CAMBRIDGE, Mass., May 29, 2019 —  Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced receipt of a Therapeutic Pipeline Program research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support development of a novel class of drugs to treat Parkinson’s disease. […]

CAMBRIDGE, Mass., September 23, 2019 — Casma Therapeutics today announced that it has been named to the 2019 Fierce 15 list by FierceBiotech for its pioneering work to harness the potential of autophagy to design powerful new medicines. The award honors the most promising private biotechnology companies in the world. Casma has built a robust product engine to identify […]

CAMBRIDGE, Mass. – October 16, 2019 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Steven Gygi, Ph.D., will join its scientific advisory board. A professor of cell biology at Harvard Medical School, Gygi brings considerable expertise in applying mass spectrometry-based technologies to the field of […]

CAMBRIDGE, Mass.- January 13, 2020 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Christian Grimm, Ph.D., and Martin Kampmann, Ph.D., will join its scientific advisory board. “Christian and Martin are at the vanguard of their respective fields, known for applying cutting edge technologies to […]

Funding led by The Column Group Proceeds will be used to advance Casma’s First-in-Class TRPML1 agonist in muscular dystrophy and enable preclinical proof-of-concept for the Company’s novel autophagy degrader platform CAMBRIDGE, Mass.-September 10, 2020 –Casma Therapeutics, Inc., a biotechnology company harnessing autophagy and the lysosome to design powerful new medicines, today announced the completion of a […]